Abstract 1949: In vivo profiling of BET degraders establishes optimal pharmacological properties that showcase distinct biological differences from BET inhibitors

MLA

Marta Issa, et al. “Abstract 1949: In Vivo Profiling of BET Degraders Establishes Optimal Pharmacological Properties That Showcase Distinct Biological Differences from BET Inhibitors.” Cancer Research, vol. 80, Aug. 2020, p. 1949. EBSCOhost, https://doi.org/10.1158/1538-7445.am2020-1949.

APA

Marta Issa, Ellen F. Vieux, Roman V. Agafonov, Mark E. Fitzgerald, Eun Sun Park, Brendon Ladd, Ryan E. Michael, David A. Proia, Linda Lee, Christopher G. Nasveschuk, David Cocozziello, & Jacob Feala. (2020). Abstract 1949: In vivo profiling of BET degraders establishes optimal pharmacological properties that showcase distinct biological differences from BET inhibitors. Cancer Research, 80, 1949. https://doi.org/10.1158/1538-7445.am2020-1949

Chicago

Marta Issa, Ellen F. Vieux, Roman V. Agafonov, Mark E. Fitzgerald, Eun Sun Park, Brendon Ladd, Ryan E. Michael, et al. 2020. “Abstract 1949: In Vivo Profiling of BET Degraders Establishes Optimal Pharmacological Properties That Showcase Distinct Biological Differences from BET Inhibitors.” Cancer Research 80 (August): 1949. doi:10.1158/1538-7445.am2020-1949.